tbuckley/cabot-search huggingface dataset:
Abstract 17583: Prognostic Value of Subclinical Myocardial Necrosis Detectable by High-Sensitivity Cardiac Troponin T in Patients With Prediabetes
Authors: W. H. Wilson Tang, Yuping Wu, Stanley L Hazen
Journal: Circulation (2017)

Background: Previous studies have identified the presence of prediabetes as being independently associated with the development of subclinical myocardial damage, as assessed by incident elevation o...
AB0646 COMPARATIVE ANALYSIS OF ASYMPTOMATIC HYPERURICEMIA AND GOUT - AN IMPACT ON KIDNEY STRUCTURE AND FUNCTION
Authors: M. Hristova, A. Kundurdzhiev, T. Kundurzhiev, R. Gancheva
Journal: Annals of the Rheumatic Diseases (2021)

Background: The significance of asymptomatic hyperuricemia (AH) continues to be debated. At the population level, asymptomatic hyperuricemia is associated with multiple comorbidities, including hypertension, coronary artery disease, diabetes and chronic kidney disease. 1 Objectives: To investigate the impact of asymptomatic hyperuricemia on renal functional and structural parameters in comparison with symptomatic gout. Methods: The subjects included in the study were divided into two groups - 46 patients with asymptomatic hyperuricemia and 18 diagnosed with gout according to ACR/EULAR 2015 criteria. 2 For renal function assessment urine analysis, albuminuria, estimated glomerular filtration rate (eGFR) based on Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation were used. Diagnostic ultrasound as well as renal biopsy were performed to evaluate structural and histological kidney changes. Statistical analysis was performed using SPSS 22.0 software (SPSS Inc, Chicago, USA). Results: There were no significant differences between the two groups on serum uric acid levels, albuminuria, and eGFR. However, erythrocyturia (p=0.047) and nephrolithiasis (p&lt;0.001) prevailed significantly in patients with gout, 66.7% and 61.1% respectively. We did not find any histological differences between the two groups regarding the number of affected glomeruli, tubular atrophy and percentage of interstitial fibrosis based on light microscopy scans. Conclusion: Our results indicate that patients with AH need renal screening since both AH and gout show similar kidney changes. Further research is needed to elucidate the role of early treatment with xanthine oxidase inhibitor for asymptomatic hyperuricemia as prevention of complications such as erythrocyturia and nephrolithiasis. References: [1]Yip K, Cohen RE, Pillinger MH. Asymptomatic hyperuricemia: is it really asymptomatic? CurrOpin Rheumatology 2020; 32(1):71-79 doi: 10.1097/BOR.0000000000000679. [2]Neogi T, Jansen TL, Dalbeth N et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatogy 2015;67(10):2557-68. doi: 10.1002/art.39254. Disclosure of Interests: None declared.
Abstract 16902: Serum Aclorein-Modified Apolipoprotein A-I is Significantly Increased in Patients With End Stage Renal Disease on Maintenance Hemodialysis
Authors: Yasunori Suematsu, Christina Park, Wanghui Jing, Melissa Soohoo, Elani Streja, Connie Rhee, Siobanth Cruz, Moti L Kashyap, Nosratola D Vaziri, Vasanthy Narayanswami, Kamyar Kalantar-Zadeh, Hamid Moradi
Journal: Circulation (2017)

Introduction: End stage renal disease (ESRD) is associated with a significantly increased risk of cardiovascular and all-cause mortality. This is most likely due to a number of factors including sy...
USPSTF recommends against screening adults in the general population for asymptomatic carotid artery stenosis
Authors: Michael Tanner
Journal: Annals of Internal Medicine (2021)

Source Citation U.S. Preventive Services Task Force, Krist AH, Davidson KW, et al. Screening for asymptomatic carotid artery stenosis: US Preventive Services Task Force recommendation statement. JAMA. 2021;325:476-81. 33528542
POS0547 METEOROLOGICAL VARIABLES HAVE DIFFERENT INFLUENCE ON CORE MEASURES OF DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS
Authors: P. Mandl, P. Studenic, F. Alasti, R. Kaltenberger, A. Kerschbaumer, T. Krennert, J. S. Smolen, D. Aletaha
Journal: Annals of the Rheumatic Diseases (2021)

Background: The notion that weather conditions may influence the symptoms and course of rheumatic and musculoskeletal diseases goes back to ancient times. However, despite the seemingly obvious relationship, previous studies assessing how meteorological variables affect pain and disease activity have yielded contradictory results. Objectives: To evaluate whether meteorological variables influence disease activity in patients with rheumatoid arthritis (RA). Methods: We assessed correlations between clinical measures of disease activity (pain, patient global assessment [PGA], tender- and swollen 28 joint counts [TJC and SJC]) and individual meteorological variables: temperature (temp.), effective (eff.) temperature, saturation vapor pressure (SVP), absolute humidity (AH), relative humidity (RH), dew point, vapor pressure (VP) and precipitation. Assessments documented in the Care for Rheumatoid Arthritis database of our institution were matched with these meteorological variables on a daily basis for a period of 12 years between 2005 and 2017 and analyzed utilizing generalized estimating equations. Patients with &lt;5 visits in the study period, those with &lt;1 visit/quarter or with no pain (VAS=0) in ≥3 consecutive visits and those living outside of the catchment area were excluded. Patients were grouped into remission or low (≤11) vs. moderate or high (&gt;11) disease activity based on the simplified disease activity index (SDAI). Results: A total of 461 patients with an average disease duration at first visit of 5.7±7.4 years, average age of 55.3±14.5 years and a mean SDAI of 22.1±12.7 were analyzed. Among patients with moderate or high disease activity, higher temp./eff. temp. and SVP were associated with lower pain, TJC and SJC (Figure 1); on the contrary, higher RH was associated with higher pain and higher SJC. In those in remission or low disease activity, higher RH, AH, VP or dew point were associated with lower PGA. Higher precipitation was associated with lower SJC. Figure 1. Association of meteorological parameters and clinical measures of disease activity . PGA: patient’s global assessment, SDAI: simplified disease activity index, SJC: swollen joint count, TJC: tender joint count. * p≤ 0.05, ** p≤ 0.01, *** p≤ 0.001 Conclusion: In this large association study of meteorological parameters with RA, both temperature and humidity parameters were modestly inversely associated with pain, TJC and SJC. Disclosure of Interests: None declared
The Impact of Frailty on the Effectiveness and Safety of Intensive Glucose Control and Blood Pressure–Lowering Therapy for People With Type 2 Diabetes: Results From the ADVANCE Trial
Authors: Tu N. Nguyen, Katie Harris, Mark Woodward, John Chalmers, Mark Cooper, Pavel Hamet, Stephen Harrap, Simon Heller, Stephen MacMahon, Giuseppe Mancia, Michel Marre, Neil Poulter, Anthony Rogers, Bryan Williams, Sophia Zoungas, Clara K. Chow, Richard I. Lindley
Journal: Diabetes Care (2021)

OBJECTIVE To develop a frailty index (FI) and explore the relationship of frailty to subsequent adverse outcomes on the effectiveness and safety of more intensive control of both blood glucose and blood pressure (BP), among participants with type 2 diabetes in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. RESEARCH DESIGN AND METHODS Cox proportional hazard models were used to estimate the effectiveness and safety of intensive glucose control and BP intervention according to frailty (defined as FI &amp;gt;0.21) status. The primary outcomes were macro- and microvascular events. The secondary outcomes were all-cause mortality, cardiovascular mortality, severe hypoglycemia, and discontinuation of BP treatment due to hypotension/dizziness. RESULTS There were 11,140 participants (mean age, 65.8 years; 42.5% women, 25.7% frail). Frailty was an independent predictor of all primary outcomes and secondary outcomes. The effect of intensive glucose treatment on primary outcomes showed some evidence of attenuation in the frail: hazard ratios for combined major macro- and microvascular events 1.03 (95% CI 0.90–1.19) in the frail versus 0.84 (95% CI 0.74–0.94) in the nonfrail (P = 0.02). A similar trend was observed with BP intervention. Severe hypoglycemia rates (per 1,000 person-years) were higher in the frail: 8.39 (6.15–10.63) vs. 4.80 (3.84–5.76) in nonfrail (P &amp;lt; 0.001). There was no significant difference in discontinuation of BP treatment between frailty groups. CONCLUSIONS It was possible to retrospectively estimate frailty in a trial population, and this FI identified those at higher risk of poor outcomes. Participants with frailty had some attenuation of benefit from intensive glucose-lowering and BP-lowering treatments.
Nanomaterials for cancer therapy: current progress and perspectives
Authors: Zhe Cheng, Maoyu Li, Raja Dey, Yongheng Chen
Journal: Journal of Hematology & Oncology (2021)

Abstract Cancer is a disease with complex pathological process. Current chemotherapy faces problems such as lack of specificity, cytotoxicity, induction of multi-drug resistance and stem-like cells growth. Nanomaterials are materials in the nanorange 1–100 nm which possess unique optical, magnetic, and electrical properties. Nanomaterials used in cancer therapy can be classified into several main categories. Targeting cancer cells, tumor microenvironment, and immune system, these nanomaterials have been modified for a wide range of cancer therapies to overcome toxicity and lack of specificity, enhance drug capacity as well as bioavailability. Although the number of studies has been increasing, the number of approved nano-drugs has not increased much over the years. To better improve clinical translation, further research is needed for targeted drug delivery by nano-carriers to reduce toxicity, enhance permeability and retention effects, and minimize the shielding effect of protein corona. This review summarizes novel nanomaterials fabricated in research and clinical use, discusses current limitations and obstacles that hinder the translation from research to clinical use, and provides suggestions for more efficient adoption of nanomaterials in cancer therapy.
Lower respiratory tract and plasma SARS-CoV-2 RNA load in critically ill adult COVID-19 patients: Relationship with biomarkers of disease severity
Authors: Beatriz Olea, Eliseo Albert, Ignacio Torres, Roberto Gozalbo-Rovira, Nieves Carbonell, José Ferreres, Sandrine Poujois, Rosa Costa, Javier Colomina, Jesús Rodríguez, María Luisa Blasco, David Navarro
Journal: Journal of Infection (2021)
AB0348 ALBUMIN-TO-GLOBULIN RATIO AS A POTENTIAL PREDICTOR OF RENAL REMISSION IN LUPUS NEPHRITIS
Authors: T. Knežević, I. Padjen, S. Bulimbašić, M. Ćorić, V. Ivković, M. Laganović, B. Anić
Journal: Annals of the Rheumatic Diseases (2021)

Background: Optimal prognostic predictors in lupus nephritis (LN) are still not clearly defined. Studies have recently shown that albumin-to-globulin ratio (A/G) is not only a good predictor of outcomes in malignancy, infection and renal disease, but is also a potential marker of increased immunoglobulin synthesis and LN activity and might be useful as a predictor of the development of LN in SLE patients. Studies on the role of A/G in predicting outcomes in LN are, however, lacking. Objectives: To assess a potential prognostic value of A/G at renal biopsy in predicting outcomes in LN. Methods: In this retrospective study we analyzed the demographic, histologic, laboratory and clinical characteristics of patients with biopsy-proven LN diagnosed between 2011 and 2020. All patients met the 1997 revised American College of Rheumatology classification criteria for SLE. Complete remission was defined as proteinuria &lt;0.5 g/day and serum creatinine within 10% from baseline, and partial remission as more than 50% reduction in proteinuria to sub-nephrotic levels and serum creatinine within 10% from baseline. Results: We have included 55 patients (80% women) with biopsy-proven LN (age at biopsy 38±13 years). On renal histology, one patient was class I LN, two patients were class II, 7 were class III, 5 were class III+V, 23 were class IV, two were class IV+V, 11 class VI and 4 had other features. Median eGFR and proteinuria at biopsy were 69 (IQR: 44, 100) mL/min/1.73 m 2 and 3.5 (2.3, 5.6) g/day, respectively. Baseline mean A/G was 1.12±0.29 and did not differ between LN classes (p=0.91). At one-year follow-up eGFR increased non-significantly (69 vs. 82 mL/min/1.73 m 2 , p=0.13) and proteinuria decreased (3.5 vs. 0.6 g/day, p&lt;0.001). Eighteen patients achieved complete remission (CR), 16 partial remission and 21 did not achieve remission. None progressed to ESRD and two patients died, both from sepsis. A/G at the time of biopsy did not differ between group which achieved CR/PR vs. no remission (p&gt;0.05; Figure 1) and was not a significant predictor of remission in a multivariate regression model (OR 5.9, 95% CI 0.6, 63.2). Conclusion: While being a potential marker for transition of SLE to LN, A/G was not showed to be a predictor of renal remission in LN. References: [1]Liu XR, et al. Lupus. 2021 Jan 6:961203320981139. [2]Kwon OC, et al. Semin Arthritis Rheum. 2018 Dec;48(3):462-466ck Disclosure of Interests: None declared
Vismodegib efficacy in unresectable trichoblastic carcinoma: A multicenter study of 16 cases
Authors: Alexandra Duplaine, Marie Beylot-Barry, Sandrine Mansard, Jean-Philippe Arnault, Jean-Jacques Grob, Hervé Maillard, Philippe Saiag, Nicolas Poulalhon, Bernard Cribier, Laurent Mortier, Maxime Battistella, Thomas Jouary
Journal: Journal of the American Academy of Dermatology (2021)
POS0632 THE LONGITUDINAL ASSOCIATIONS OF METHOTREXATE AND BIOLOGIC USE ON HOSPITAL ADMISSION FOR RHEUMATOID ARTHRITIS PATIENTS IN WESTERN AUSTRALIA POPULATION (1995- 2014)
Authors: K. Almutairi, J. Nossent, D. Preen, H. Keen, C. Inderjeeth
Journal: Annals of the Rheumatic Diseases (2021)

Background: Rheumatoid arthritis (RA) carries a substantial burden for patients and society in terms of morbidity, enduring disability, and costs [1]. The Australian Pharmaceutical Benefits Scheme (PBS) has subsidised biological disease-modifying anti-rheumatic drugs (B-DMARDs) since 2003 [2]. Objectives: We examined the impact of B-DMARDs availability on RA hospitalisation rate in the Western Australia (WA) population pre- and post- B-DMARDs introduction to the PBS (1995-2002 and 2003-2014). Methods: Population PBS dispensing data for WA of DMARD were obtained and converted to defined daily doses (DDD)/1000 population/day using the WA population census. RA inpatient records were extracted from the WA Hospital Morbidity Data Collection using ICD-9 codes 714 and ICD-10 codes M05.00–M06.99). Principal component analysis (PCA) was applied to determine the relationship between DMARDs use and RA hospital admission rates. Results: There was a total of 17,125 patients who had 50,353 admissions with a diagnostic code for RA during the study period. DMARD use for RA rose from 1.45 to 3.19 DDD/1000 population/day over 1995-2014 (Figure 1). In 1995-2002, the number of RA admissions fell from 7.9 to 2.6 per 1000 hospital separations, then dropped further from 2.9 to 1.9 per 1000 hospital separations in 2003-2014. Based on PCA analysis, conventional DMARDs (methotrexate) and B-DMARDs dispensing had an inverse association with hospital admissions for RA. Conclusion: The increased availability of conventional and biological DMARDs for RA was associated with a significant decline in hospital admissions for RA patients in WA. References: [1]Boonen A, Severens JL (2011) The burden of illness of rheumatoid arthritis. Clin Rheumatol 30:3-8. [2]Medicare Australia (2020) Pharmaceutical Benefits Schedule statistics. http://medicarestatistics.humanservices.gov.au/statistics/pbs_item.jsp . Figure 1. The hospital separations and total drugs use patterns of RA in 1995-2014 in Western Australia. Acknowledgements: Supported by an Australian Government Research Training Program PhD Scholarship at the University of Western Australia. Disclosure of Interests: Khalid Almutairi: None declared, Johannes Nossent Speakers bureau: Janssen, David Preen: None declared, Helen Keen Speakers bureau: Pfizer Australia, Abbvie Australia, Charles Inderjeeth Speakers bureau: bureau: Eli Lilly
Enzymatically-degradable hydrogel coatings on titanium for bacterial infection inhibition and enhanced soft tissue compatibility via a self-adaptive strategy
Authors: Jin Leng, Ye He, Zhang Yuan, Bailong Tao, Ke Li, Chuanchuan Lin, Kun Xu, Maowen Chen, Liangliang Dai, Xuemin Li, Tony Jun Huang, Kaiyong Cai
Journal: Bioactive Materials (2021)

Ideal percutaneous titanium implants request both antibacterial ability and soft tissue compatibility. ZnO structure constructed on titanium has been widely proved to be helpful to combat pathogen contamination, but the biosafety of ZnO is always questioned. How to maintain the remarkable antibacterial ability of ZnO and efficiently reduce the corresponding toxicity is still challenging. Herein, a hybrid hydrogel coating was constructed on the fabricated ZnO structure of titanium, and the coating was proved to be enzymatically-degradable when bacteria exist. Then the antibacterial activity of ZnO was presented. When under the normal condition (no bacteria), the hydrogel coating was stable and tightly adhered to titanium. The toxicity of ZnO was reduced, and the viability of fibroblasts was largely improved. More importantly, the hydrogel coating provided a good buffer zone for cell ingrowth and soft tissue integration. The curbed Zn ion release was also proved to be useful to regulate fibroblast responses such as the expression of CTGF and COL-I. These results were also validated by in vivo studies. Therefore, this study proposed a valid self-adaptive strategy for ZnO improvement. Under different conditions, the sample could present different functions, and both the antibacterial ability and soft tissue compatibility were finely preserved.
AB0717 PREVALENCE OF MIGRAINE AND NEUROPATHIC PAIN AMONG PATIENTS WITH RHEUMATIC DISEASES
Authors: S. Miladi, M. Yasmine, A. Fazaa, S. Mariem, K. Ouenniche, L. Souebni, S. Kassab, S. Chekili, K. Ben Abdelghani, A. Laatar
Journal: Annals of the Rheumatic Diseases (2021)

Background: Pain in rheumatic diseases (RD) is primarily due to mechanical or inflammatory mechanism, but neuropathic pain (NP) component is yet to be fully evaluated and described, with a particular attention to the distinction with nociceptive pain [1]. Objectives: The aim of our study was to assess the prevalence of migraine and neuropathic pain in patients with RD and to explore factors associated with NP. Methods: Prospective study including patients with rheumatoid arthritis (RA) and spondylarthritis (SpA) were invited to complete a validated self-assessment questionnaires. Sociodemographic data as well as disease related characteristics were recorded. Migraine was diagnosed according to the IHS migraine diagnostic criteria. NP was evaluated using DN4 (Douleur Neuropathique 4 Questions) and Pain DETECT questionnaire (PDQ). Neuropathic pain was retained in case of a total score of 4 or more at DN4-interview questionnaire or a score ≥19 with the PDQ. Results: A total of 60 patients with RD were included (42 RA/18 SpA). Females outnumbered males (sex-ratio=1.7). The mean age was 51.3 ± 13.1 years [18-75] and the mean disease duration was 11.9 ±5.6 [1-23] years. The prevalence of migraine was 15%. This latter was higher among women than men and among RA patients than SpA (18% vs 9%, 16.6% vs 11.2%) with no statistically significant correlation (p=0,329, 0,581 respectively). Parameters associated with a higher prevalence of migraine were an older age (p=0,042). However, there was no correlation between the presence of migraine and the type of the RD, disease duration or the level of anxiety (p=0,059, p=0,459 respectively). Chronic pain with neuropathic characteristics was found in 21.7% with the DECT score and 16.7% with DN4 questionnaire. NP was most prevalent among patients with comorbidities (28.5% vs 6%, p=0.021) and with higher body mass index (p=0.01). Prevalence was significantly higher in the RA group (19%) than in the SpA group (11%) without a statistically significant correlation (p=0.45). Similarly, NP was not associated with Salazopyrine intake (p=0.9). Conclusion: We found a high prevalence of migraine and NP in our sample of patients with RD. It seems therefore important to check the presence of migraine or NP especially in patients with comorbidities and older ones. References: [1]Bailly F, Cantagrel A, Bertin P, et al. Part of pain labelled neuropathic in rheumatic disease might be rather nociplastic. RMD Open. 2020;6:e001326. Disclosure of Interests: None declared
Thromboembolic Events in the South African Ad26.COV2.S Vaccine Study
Authors: Simbarashe Takuva, Azwidhwi Takalani, Nigel Garrett, Ameena Goga, Jonny Peter, Vernon Louw, Jessica Opie, Barry Jacobson, Ian Sanne, Linda Gail-Bekker, Glenda Gray
Journal: New England Journal of Medicine (2021)

Rare Thromboembolic Events among Vaccinated South Africans Among 288,368 South African health care workers who received the Ad26.COV2.S vaccine, no cases of vaccine-induced immune thrombotic thromb...
Defining the Transcriptional Code That Specifies Sinusoidal Endothelial Cells in the HSPC Niche
Authors: Elliott J. Hagedorn, Julie R. Perlin, Clara Mao, Shelby E. Redfield, Madeleine L. Daily, Samantha H. Collins, Christopher R. D'Amato, Raquel Riquelme, Brian Li, Samuel J. Wattrus, Karoline Holler, Alexander van Oudenaarden, Jan Philipp Junker, Leonard I. Zon
Journal: Blood (2017)